|Bid||0.2000 x N/A|
|Ask||0.2200 x N/A|
|Day's Range||0.2000 - 0.2400|
|52 Week Range||0.2000 - 0.4500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.40|
Subscribe to Yahoo Finance Plus to view Fair Value for MAP.AX
BRISBANE, Australia, May 26, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") has signed a strategic partnership agreement ("Agreement") with nib Holdings Limited (ASX: NHF) backed digital healthcare company Midnight Health, to deliver a personalised health service to the Australian consumer market.
BRISBANE, Australia, May 05, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program significantly earlier than expected. This will enable preclinical animal studies to be brought forward to the end of calendar year 2022 which is approximately 12 months ahead of schedule.
BRISBANE, Australia, April 06, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce Professor Trent Munro will be joining the company as Senior Vice President of Therapeutics. Professor Munro has over 25 years’ research and development experience, including with multinational biopharmaceutical company Amgen.